Circulation: Cardiovascular Quality and Outcomes: Published
Apr 2024
TAKE-HOME MESSAGE
This study
used data from the FAST-MI program to examine the effect of lipid-lowering
therapy (LLT) (atorvastatin ≥40 mg or equivalent or any combination of a statin
and ezetimibe) intensity on long-term mortality in 2258 patients aged 80 years
or older who experienced an acute myocardial infarction.
High-dose
LLT was associated with a significantly lower risk of 5-year mortality than
that of no LLT, whereas conventional-intensity LLT showed no significant
association with mortality. Propensity score matching confirmed these findings,
showing a 22% lower risk of mortality with high-intensity LLT.
This study suggests that older patients should not be denied high-intensity Lipid-Lowering Therapy (LLT) after an acute myocardial infarction as it is linked to a reduced risk of all-cause mortality.
Background: Older
people are underrepresented in randomized trials. The association between
lipid-lowering therapy (LLT) and its intensity after acute myocardial
infarction and long-term mortality in this population deserves to be assessed.
Methods: The FAST-MI
(French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial
Infarction) program consists of nationwide French surveys including all
patients admitted for acute myocardial infarction ≤48 hours from onset over a
1- to 2-month period in 2005, 2010, and 2015, with long-term follow-up.
Numerous data were collected and a centralized 10-year follow-up was organized.
The present analysis focused on the association between prescription of LLT
(atorvastatin ≥40 mg or equivalent, or any combination of statin and ezetimibe)
and 5-year mortality in patients aged ≥80 years discharged alive. Cox
multivariable analysis and propensity score matching were used to adjust for
baseline differences.
Results: Among the
2258 patients aged ≥80 years (mean age, 85±4 years; 51% women; 39% ST-segment
elevation myocardial infarction; 58% with percutaneous coronary intervention),
415 were discharged without LLT (18%), 866 with conventional doses (38%), and
977 with high-dose LLT (43%). Five-year survival was 36%, 47.5%, and 58%,
respectively. Compared with patients without LLT, high-dose LLT was
significantly associated with lower 5-year mortality (adjusted hazard ratio,
0.78 [95% CI, 0.66-0.92]), whereas conventional-intensity LLT was not (adjusted
hazard ratio, 0.93 [95% CI, 0.80-1.09]). In propensity score-matched cohorts
(n=278 receiving high-intensity LLT and n=278 receiving no statins), 5-year
survival was 52% with high-intensity LLT at discharge and 42% without statins
(hazard ratio, 0.78 [95% CI, 0.62-0.98]).
Conclusions: In these
observational cohorts, high-intensity LLT at discharge after acute myocardial
infarction was associated with reduced all-cause mortality at 5 years in an
older adult population. These results suggest that high-intensity LLT should
not be denied to patients on the basis of old age.
Comments
You must login to write comment